Southeast Asia has recently emerged as a dynamic and rapidly evolving region in the global pharmaceutical industry. With its population of more than 688 million people, about 8.5% of the world's population, the potential for developing a thriving biopharma ecosystem in this part of the world is immense. This session will gather investors, pharma and CDMO executives and strategists to explore the critical factors and strategies required to build a successful and competitive biopharma ecosystem in Southeast Asia.